Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: Cancer and Leukemia group B (CALGB) 30106, a CALGB-stratified phase II trial.
- Citation:
- J Thorac Oncol vol 5 (9) 1382-90
- Year:
- 2010
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- Yes
- Book Volume:
- Parents:
- None
- Children:
- None
- Program:
- OGC
- Primary Committee:
- Respiratory
- Sec. Committees:
- Pharmas:
- Grants:
- Corr. Author:
- Authors:
- Neal Ready Pasi A Jänne Jeffrey Bogart Thomas Dipetrillo Jennifer Garst Stephen Graziano Lin Gu Xiaofei Wang Mark R Green Everett E Vokes
- Networks:
- Study
- CALGB-30106
- Multiple Studies, or Legacy Studies in Alliance Study:
- CALGB-150508
- Phases:
- 2, N/A
- Keywords:
- Adenocarcinoma, Aged, Antineoplastic Combined Chemotherapy Protocols, Carboplatin, Carcinoma, Large Cell, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Combined Modality Therapy, Drug Resistance, Neoplasm, Female, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Neoplasm Staging, Paclitaxel, Proto-Oncogene Proteins, Proto-Oncogene Proteins p21(ras), Quinazolines, Radiotherapy, Receptor, Epidermal Growth Factor, Survival Rate, Treatment Outcome, ras Proteins